Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: a real …
XL Marston, R Wang, YC Yeh, L Zimmermann… - International journal of …, 2022 - Elsevier
Background The aim of the study was to compare the real-world effectiveness and safety in
atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants …
atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants …
How to handle a delayed or missed dose of edoxaban in patients with non‐valvular atrial fibrillation? A model‐informed remedial strategy
Aims Edoxaban is a non‐vitamin K antagonist oral anticoagulant (NOAC) widely used for the
long‐term prevention of stroke in patients with non‐valvular atrial fibrillation (NVAF) …
long‐term prevention of stroke in patients with non‐valvular atrial fibrillation (NVAF) …
[PDF][PDF] Edoxaban Anticoagulation in Atrial Fibrillation: Real-World Data and Evidence.
S Çay, M Kasap - Archives of the Turkish Society of …, 2023 - jag.journalagent.com
Atrial fibrillation (AF) and stroke are two prevalent health conditions with many shared risk
factors. Over the past two decades, non-vitamin K antagonist oral anticoagulants (NOACs) …
factors. Over the past two decades, non-vitamin K antagonist oral anticoagulants (NOACs) …
Epidemiologie ausgewählter Infektionen des Gastrointestinaltraktes in Deutschland
L Zimmermann - ul.qucosa.de
Abstract (DE) Zu den häufigsten intraabdominellen Infektionen gehören der bakteriell
bedingte, pyogene Leberabszess (PLA) sowie die Clostridioides-difficile-Infektion (CDI). Im …
bedingte, pyogene Leberabszess (PLA) sowie die Clostridioides-difficile-Infektion (CDI). Im …